DESCRIPTION OF BUSINESS (Details Narrative) - $ / shares |
9 Months Ended | ||
|---|---|---|---|
Jun. 15, 2021 |
Jan. 31, 2022 |
Apr. 30, 2021 |
|
| Subsidiary, Sale of Stock [Line Items] | |||
| Description of novel products | The Company’s primary focus is Alzheimer’s disease (“Alzheimer’s”). With two current and future product candidates, Alzamend aims to bring treatments and/or potential cures to market as quickly as possible. The Company’s current pipeline consists of two novel therapeutic drug candidates (collectively, the “Technology”): (i) a patented ionic cocrystal technology delivering a therapeutic combination of lithium, proline and salicylate, known as AL001 or LiProSal, through two royalty-bearing exclusive worldwide licenses from the University of South Florida Research Foundation, Inc. (the “Licensor”), and (ii) a patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer’s, known as AL002 or CA022W, through a royalty-bearing exclusive worldwide license with Licensor | ||
| Common stock, par value (in dollars per share) | $ 0.0001 | $ 0.0001 | |
| Issuance of common stock for restricted stock awards (in shares) | 212,500 | ||
| Series A Preferred Stock [Member] | |||
| Subsidiary, Sale of Stock [Line Items] | |||
| Preferred stock, outstanding | 750,000 | 750,000 | |
| IPO [Member] | |||
| Subsidiary, Sale of Stock [Line Items] | |||
| Issuance of common stock for restricted stock awards (in shares) | 2,875,000 | ||
| Public offering price | $ 5.00 | ||
| IPO [Member] | Series A Preferred Stock [Member] | |||
| Subsidiary, Sale of Stock [Line Items] | |||
| Preferred stock, outstanding | 15,000,000 | ||
| IPO [Member] | Digital Power Lending [Member] | |||
| Subsidiary, Sale of Stock [Line Items] | |||
| Stock ipo purchased | 2,000,000 |